Free tool
FAERS Monitor: Renvela
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022318 or its brand name (Renvela, Sevelamer Carbonate). Reports on generic versions are filed under their own applications.
Reports
11,505
Serious
5,643
49% of reports
Hospitalization
3,059
Death reported
1,228
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- constipation2,548
- diarrhoea1,057
- pruritus1,009
- nausea819
- chronic kidney disease676
- end stage renal disease674
- renal failure666
- death628
- vomiting533
- acute kidney injury515
- abdominal pain308
- nephrogenic anaemia298
- dyspnoea294
- fatigue267
- flatulence251
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 4 |
| 2009 | 54 |
| 2010 | 74 |
| 2011 | 165 |
| 2012 | 239 |
| 2013 | 1,071 |
| 2014 | 3,605 |
| 2015 | 890 |
| 2016 | 678 |
| 2017 | 875 |
| 2018 | 824 |
| 2019 | 790 |
| 2020 | 487 |
| 2021 | 368 |
| 2022 | 277 |
| 2023 | 262 |
| 2024 | 273 |
| 2025 | 355 |
| 2026 | 214 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,654 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| nephrogenic anaemiaSignal | 298 | 125.6 | 111.9 | 34,363 |
| end stage renal diseaseSignal | 674 | 70.1 | 65.1 | 44,193 |
| constipationSignal | 2,548 | 21.6 | 20.9 | 49,971 |
| chronic kidney diseaseSignal | 676 | 16.4 | 15.2 | 9,710 |
| renal failureSignal | 666 | 9.2 | 8.6 | 4,872 |
| flatulenceSignal | 251 | 8.1 | 7.2 | 1,558 |
| acute kidney injurySignal | 515 | 6.2 | 5.7 | 2,234 |
| pruritusSignal | 1,009 | 4.8 | 4.5 | 3,090 |
| diarrhoeaSignal | 1,057 | 3.0 | 2.8 | 1,446 |
| abdominal painSignal | 308 | 2.4 | 2.2 | 258 |
| vomitingSignal | 533 | 2.1 | 1.9 | 302 |
| nausea | 819 | 1.9 | 1.8 | 357 |
| death | 628 | 1.3 | 1.2 | 54 |
| dyspnoea | 294 | 0.9 | 0.8 | 1 |
| fatigue | 267 | 0.6 | 0.6 | 61 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.